Diet ESG

Podcast
15 min listen
Namita Nair
April 12, 2023
In this episode

This week we discuss the new anti-obesity drugs that many have claimed could spell an end to the world’s obesity epidemic. But ESG and diseases are not so straight forward. For example, we include diabetes medication but not obesity medication in our access to healthcare key issue. Why is that? We explore the topic in this week’s episode.
Listen
Spotify
Apple
YouTube
Featuring
Namita Nair
Namita Nair
Vice President, MSCI Research

Subscribe today
to have insights delivered to your inbox.

ESG Now Podcast

The world of ESG explored. A rotating cast of environmental, social, and governance researchers join hosts Mike Disabato and Bentley Kaplan as they discuss the most pressing news of the week. But in an enjoyable way.
Previous episodes

MSCI ESG Healthcare Funds and SDG 3

We studied all ETFs and mutual funds in our coverage that invest in healthcare and allied industries to assess the degree of fund alignment with the UN's Sustainable Development Goal 3. Overall, we found relatively little alignment.
Learn more

Bacteria Rising: Another Health Crisis Looms

Despite years of warnings from epidemiologists, the COVID-19 outbreak caught the world off guard.
Read more

The content of this page is for informational purposes only and is intended for institutional professionals with the analytical resources and tools necessary to interpret any performance information. Nothing herein is intended to recommend any product, tool or service. For all references to laws, rules or regulations, please note that the information is provided “as is” and does not constitute legal advice or any binding interpretation. Any approach to comply with regulatory or policy initiatives should be discussed with your own legal counsel and/or the relevant competent authority, as needed.